$3.69 Million in Sales Expected for XOMA Co. (XOMA) This Quarter

Wall Street brokerages forecast that XOMA Co. (NASDAQ:XOMA) will report $3.69 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for XOMA’s earnings, with the lowest sales estimate coming in at $1.55 million and the highest estimate coming in at $5.82 million. XOMA reported sales of $260,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 1,319.2%. The business is expected to issue its next earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that XOMA will report full year sales of $3.69 million for the current fiscal year, with estimates ranging from $18.70 million to $19.79 million. For the next year, analysts forecast that the firm will post sales of $20.28 million per share, with estimates ranging from $18.86 million to $21.70 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover XOMA.

XOMA (NASDAQ:XOMA) last issued its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.19. The business had revenue of $5.36 million during the quarter, compared to analyst estimates of $4.12 million. XOMA had a negative return on equity of 130.44% and a net margin of 27.49%.

A number of equities research analysts have weighed in on XOMA shares. Zacks Investment Research lowered XOMA from a “hold” rating to a “sell” rating in a report on Saturday, March 17th. HC Wainwright set a $49.00 target price on shares of XOMA and gave the stock a “buy” rating in a research note on Friday, March 9th. ValuEngine raised shares of XOMA from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. TheStreet raised shares of XOMA from an “e+” rating to a “c-” rating in a research note on Wednesday, November 29th. Finally, Wedbush reaffirmed a “buy” rating and issued a $33.00 target price on shares of XOMA in a research note on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $38.33.

Several large investors have recently modified their holdings of XOMA. Bank of Montreal Can purchased a new position in XOMA during the 4th quarter worth $138,000. Acadian Asset Management LLC purchased a new stake in XOMA in the 4th quarter valued at approximately $152,000. Gotham Asset Management LLC purchased a new stake in XOMA in the 4th quarter valued at approximately $267,000. Wells Fargo & Company MN boosted its holdings in XOMA by 4,288.9% in the 4th quarter. Wells Fargo & Company MN now owns 8,295 shares of the biotechnology company’s stock valued at $295,000 after purchasing an additional 8,106 shares in the last quarter. Finally, Alps Advisors Inc. purchased a new stake in XOMA in the 4th quarter valued at approximately $321,000. Institutional investors own 38.90% of the company’s stock.

Shares of XOMA stock traded up $0.02 on Thursday, reaching $21.47. The company had a trading volume of 131,761 shares, compared to its average volume of 254,411. The company has a market cap of $178.83, a P/E ratio of -40.51 and a beta of 3.03. XOMA has a 52 week low of $5.86 and a 52 week high of $37.25. The company has a debt-to-equity ratio of 2.52, a current ratio of 5.96 and a quick ratio of 5.96.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3300090/3-69-million-in-sales-expected-for-xoma-co-xoma-this-quarter.html.

XOMA Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Deutsche Bank AG Has $2.25 Million Position in Sturm Ruger & Co
Deutsche Bank AG Has $2.25 Million Position in Sturm Ruger & Co
Cypress Capital Management LLC Buys 973 Shares of PepsiCo
Cypress Capital Management LLC Buys 973 Shares of PepsiCo
Cornerstone Capital Management Holdings LLC. Decreases Position in Bank of America
Cornerstone Capital Management Holdings LLC. Decreases Position in Bank of America
SunPower  Cut to Underperform at Bank of America
SunPower Cut to Underperform at Bank of America
Financial Review: Amyris Biotechnologies  versus The Competition
Financial Review: Amyris Biotechnologies versus The Competition
Piper Jaffray Comments on Bank of Hawaii’s Q2 2018 Earnings
Piper Jaffray Comments on Bank of Hawaii’s Q2 2018 Earnings


© 2006-2018 Ticker Report. Google+.